SIGHT.PA GenSight Biologics EURONEXT after hours: down 16.15% to €0.09, catalysts ahead

SIGHT.PA stock fell sharply in after-hours trading on 11 Mar 2026, dropping 16.15% to €0.09 on volume of 2,727,402 shares. That move pushed GenSight Biologics S.A. (SIGHT.PA) well below its 200‑day average of €0.13 and showed a relative surge in selling versus the 50‑day average volume of 1,740,345. Investors are focused on near-term clinical and cash‑runway catalysts, including the company’s earnings/earnings‑related update scheduled for 20 Mar 2026, which likely amplified after‑hours pressure on EURONEXT Europe trading.

SIGHT.PA stock price action and liquidity

Today’s main fact: GenSight Biologics (SIGHT.PA) closed after hours at €0.09, down 16.15% from the previous close of €0.11. The session registered a total volume of 2,727,402 shares against an average volume of 1,740,345, producing a relative volume of 3.49, which signals unusually heavy trading.

Intraday range and technical context were extreme: the day low was €0.09, the high €0.10, and the stock opened at €0.10 — these moves illustrate aggressive selling in the after‑hours window on EURONEXT in Europe.

SIGHT.PA stock fundamentals and valuation

GenSight Biologics reports an EPS of -0.13 and a reported PE of -0.78, reflecting current losses and negative earnings. Market capitalisation stands at €19,344,957.00 with 190,029,052 shares outstanding, while price to sales is 20.47 and price to book is -0.41, indicating a valuation disconnect for this clinical‑stage biotech.

Key balance and cash metrics are thin: cash per share is €0.00 (reported €0.00 when rounded to two decimals) and current ratio is 0.11, which increases liquidity risk ahead of the upcoming earnings announcement. These ratios connect directly to the selloff as investors price in funding or partnership needs.

SIGHT.PA stock technicals and momentum

Technical indicators show strong short‑term momentum but potential exhaustion: RSI is 75.51 (overbought), ADX 43.46 (strong trend), and MFI 94.64 (heavy buying earlier then fast outflows). The 50‑day price average is €0.09 and the 200‑day average is €0.13, highlighting that the share has lost longer‑term support.

Volume indicators (OBV 19,373,882.00) and a high ATR (€0.01) suggest elevated volatility; traders should expect swift moves if the company’s Mar 20 update changes clinical or cash expectations.

SIGHT.PA stock news, catalysts and market drivers

The immediate trigger for today’s after‑hours weakness appears tied to sector comparisons and upcoming company events rather than a single public release. Investors often sell small‑cap biotechs like GenSight ahead of binary clinical or earnings dates because downside risk is asymmetric for low‑liquidity names. Recent comparator screens include GenSight alongside peers on Investing.com, which investors use to benchmark clinical and valuation risk source and in competitor lists for Onxeo where SIGHT appears in peer comparison tools source.

Given the company’s clinical‑stage profile (lead programs LUMEVOQ and GS030), trial readouts or guidance revisions around 20 Mar 2026 will likely drive the next sustained move.

Meyka AI rates SIGHT.PA with a score out of 100

Meyka AI rates SIGHT.PA with a score out of 100: 72.50 (Grade B+ | Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Company rating services remain mixed: a third‑party score dated 10 Mar 2026 lists a C / Sell view driven by weak DCF and several poor leverage metrics — we show both views to highlight disagreement between quantitative model inputs and forward-looking recovery scenarios. These grades are not guaranteed and we are not financial advisors.

SIGHT.PA stock forecast, price targets and risk outlook

Meyka AI’s forecast model projects a near‑term monthly level of €0.08, versus the current €0.0914, implying a model‑based downside of -12.45% from today’s price; forecasts are model‑based projections and not guarantees. A conservative downside price target is €0.05 (implied -45.28%), a base case aligns with the €0.08 forecast (implied -12.45%), and an optimistic upside target if clinical or partnership news is positive would be €0.20 (implied +118.82%).

Key risks: thin cash runway (current ratio 0.11), negative operating cash flow per share -€0.06, and binary clinical outcomes. Key opportunities: successful Phase III readouts or a strategic partnership could materially re‑rate the stock given low market capitalisation and high optionality.

Final Thoughts

SIGHT.PA stock’s after‑hours fall of 16.15% to €0.09 on 11 Mar 2026 reflects heightened risk aversion ahead of a company update and persistent liquidity concerns for small EU biotechs. Fundamentals show negative EPS (-0.13) and tight liquidity (current ratio 0.11), while technicals show short‑term overbought exhaustion (RSI 75.51) and elevated volume (2,727,402 shares). Meyka AI’s models project a near‑term level of €0.08, implying -12.45% downside from today’s price; this projection is model‑based and not a guarantee. Our balanced view: traders should treat SIGHT.PA as a high‑volatility speculative name where binary clinical catalysts and funding signals will dictate direction. We present a conservative €0.05 downside target and an optimistic €0.20 upside case tied to positive clinical or partner outcomes. Meyka AI, an AI‑powered market analysis platform, factors these scenarios into its grade and forecasts but recommends investors perform their own due diligence before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.